Description
Orphazyme is pioneering the development of a new type of medical treatment.
History
Orphazyme was founded in Denmark in 2009 based on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature. One of the lead authors of that paper, Thomas Kirkegaard Jensen, is a founder of Orphazym and Chief Scientific Officer.
Today, Orphazym has translated that scientific discovery into a late-stage clinical development program. The company is working to obtain regulatory approvals that will allow the company's to bring a novel treatment to patients, applying the company's knowledge of heat shock proteins (HSPs) for the benefit of people living with rare neurodegenerative diseases.